title: [Invasive fungal infection in critically ill patient: role of micafungin].
abstract: The invasive fungal infections (IFIs) have increased in critically ill patients in recent years and are a serious complication that determine the evolution and prognosis of critically ill patients, especially invasive candidiasis (IC)and candidemia. Fortunately, treatment options for these infections have increased and there is a large arsenal of antifungal agents. This review of the literature, using PubMed and Cochrane databases, assesses the situation of the IFIs in critically ill patients and discusses the role of micafungin in this context. The broader spectrum of this candin, which gets the antifungal effect with lower MICs and that translates into greater clinical efficacy with a lower rate of adverse effects and easier to use, with proven cost-effectiveness compared with other antifungal, position micafungin as a useful therapeutic option for the management of invasive candidiasis / candidemia in critically ill patients.
authors.affiliation: Servicio de Medicina Intensiva, Hospital Clínico San Carlos, Madrid, Spain. mnietocabrera@hotmail.com
authors.forename: Mercedes
authors.initials: M
authors.lastname: Nieto Cabrera
authors.forename: Elena Escudero
authors.initials: EE
authors.lastname: López-Cepero
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology; D016638:Critical Illness; D054714:Echinocandins / Q000627:therapeutic use*; D005658:Fungi / Q000187:drug effects; D006801:Humans; D055666:Lipopeptides / Q000627:therapeutic use*; D000077551:Micafungin; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology; D011379:Prognosis
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin